{"id":"NCT03771963","sponsor":"Takeda","briefTitle":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults","officialTitle":"An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-28","primaryCompletion":"2019-10-14","completion":"2020-03-13","firstPosted":"2018-12-11","resultsPosted":"2021-06-07","lastUpdate":"2021-06-07"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever"],"interventions":[{"type":"BIOLOGICAL","name":"Tetravalent Dengue Vaccine (TDV)","otherNames":[]}],"arms":[{"label":"Tetravalent Dengue Vaccine (TDV)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.","primaryOutcome":{"measure":"Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120","timeFrame":"One month post second dose (Day 120)","effectByArm":[{"arm":"Tetravalent Dengue Vaccine (TDV)","deltaMin":557.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["40099800","37846724"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":200},"commonTop":[]}}